At first, you need to have a little introduction to these two companies. They both are pharmaceuticals. They provide medicines and research related to medicine. What are they and what do they do? Here’s the introduction.
An Irish–tax registered manufacturer, known as Mallinckrodt Pharmaceuticals of specialty pharmaceuticals, generic drugs, and imaging agent in 2017 generated 90% of sales from the U.S. healthcare system. With such a large network, it is one of the finest and leading pharmaceuticals.
A biotechnology company that develops therapeutic gene technology based on RNA interference. They are responsible and have major involvement in developmental research of targeted RNAi therapeutics for the treatment of serious diseases.
What is RNAi?
RNAi or RNA Interference is a biological process in our internal body. RNA interferes with RNA to cut it down from double-stranded RNA to single and then to further more pieces. This process inhibits gene expression or translation by targeting RNA and neutralizing it.
Mallinckrodt and Silence Therapeutics Partnership
Mallinckrodt is the finest and leading pharmaceutical you can find. With such a vast network, it has the power to change, the power to reach out and help maximum. The one problem they were facing was lack of research and information about RNAi. Silence Therapeutics had all the knowledge of RNAi. With that knowledge, you could even treat deadly cancerous diseases. You may have guessed it until now.
One of the ten principles of microeconomics says Trade can make everyone better off. So, Mallinckrodt holding power to reach out and change and Silence Therapeutics with the information made a deal and became partners.
There were some noticeable points made at the time of their partnership. Some of them are mentioned below.
• This partnership will allow Silence’s platform in the field of RNAi technology to advance. With more advancement, new ways would come out to solve deadly diseases.
• The agreement provides Mallinckrodt with an exclusive worldwide license for one preclinical asset that targets a specific protein in the complement pathway, C3 (SLN500), and an option for up to two additional assets with different complement protein targets
• $20 million upfront payment, long-term development, commercial milestones, and royalties on net sales will be received by Silence.
This collaboration will allow both companies to develop an RNAi drug. This drug would be a group of proteins that are involved in the immune system to fight different diseases. These proteins play an important role in the development of inflammation.
These proteins are also considered to contribute to the pathogenesis of many diseases, including autoimmune diseases. This would change the medical world and show it a better path to find more ways to fight deadly diseases.
Not only will this partnership help in the medical field but would also leave an impact on other companies to indulge themselves in these healthy partnerships to produce the best possible outcome. The business world is a dirty place, and it needs to have examples like these.